Building the Biobank of Tomorrow

From Static Repositories to Living Intelligence Systems

Building on our previous exploration of Four Archetypes, One Revolution: How AI is Re-Architecting Life Sciences, this article examines how real-world data (RWD) biobanks are evolving from frozen archives into dynamic, AI-powered platforms that accelerate the journey from Emerging to Leader organizations.

Healthcare is at a turning point. Think of how financial institutions once stored cash in vaults, then transformed that cash into liquid, transactable capital — and growth exploded. In life sciences, we stand at a similar inflection: the era of real-world-data (RWD) banking.

Traditional biobanks have built value by assembling samples and data. But the next leap is to turn those dormant deposits — each biopsy, image, outcome — into liquid intelligence: dynamic assets that fuel biomolecular digital twins, actionable insights and continuous innovation.

A recent review of medical digital twins notes that virtual models of health and disease “integrate real-time data and simulations to predict, prevent, and personalize treatments.” Meanwhile, knowledge graphs are emerging as the foundational architecture for such systems — connecting multimodal data, enabling semantic reasoning, and powering simulation.

Recent findings underscore the biobank transformation. According to a Forbes analysis of the biobank industry and market research, the global biobanking market (TAM) is projected to reach $130.16 billion by 2032, growing at a CAGR of 6.8%. Yet most biobanks remain trapped in the “Emerging” archetype we identified previously — disconnected pilots, fragmented data, and limited AI integration. With the right computational layer, biobanks can move from being sources of samples to being strategic partners in target discovery, trial design, and population-level risk modelling.

The AI Maturity Gap for Biobanks

Most biobanks today remain Emerging — rich in samples but poor in synthesis. They face four structural constraints:

• Fragmented infrastructure: Samples stored at −80 °C with minimal digital traceability.
• Siloed data: Clinical, imaging, omics, and outcomes data reside in separate systems.
• Manual workflows: Tracking, quality control, and consent management are not automated.
• Limited analytics: Insights remain descriptive, not predictive or prescriptive.

Yet, the biobank of the future will function as a central bank of biological intelligence — a cognitive system where every dataset, sample, and model compounds in value.

Many studies now illustrate how digital twins of patient health require precisely these elements — multi-scale data integration, semantic context, and real-time reasoning. For example, one published framework noted that digital twin systems “must integrate data from multiple biological scales, develop computational methods that unify them, and build interoperable models that learn from each other. While digital twin (DT), knowledge graph (KG), and real-world data (RWD) frameworks are widely discussed, few studies address the full lifecycle that defines a true biobank intelligence pipeline:

From physical sample (−80 °C) → metadata → linkage to RWD → knowledge graph → digital twin → decision or clinical output.

We typically treat these domains in isolation — DTs as simulation systems, KGs as semantic infrastructures, RWD as observational evidence — but the next generation of biobanks must integrate them end-to-end into a continuously learning ecosystem.

Archetypes in Biobank Evolution

As per market research reports and publications, the transformation is already underway:

• North America leads global market share, fueled by mature infrastructure and R&D investment.
• Genomic biobanking is a fast growing segment — precisely where AI delivers the great return.
• Public–private partnerships are accelerating analytics innovation, turning static repositories into dynamic engines of discovery.

The Technical Architecture: Biobank Digital Twin Platform

Knowledge Graph (the brain)

The “cognitive reserve” and “neural economy” we’ve described aren’t just metaphors — they are powered by a specific and powerful technology: a Domain-Specific Knowledge Graph (KG) built on Real-World Data (RWD). If the RWD Digital Twin is the living, dynamic model, the Knowledge Graph is its intelligent, evolving brain.

From Data Warehouses to Intelligent Networks

Traditional data warehouses were built like vaults: static repositories, excellent for storing historical RWD but slow to yield predictive insights. The architecture of a Leader organization transcends this. It’s not a data warehouse but an intelligent network.

Powered by the Knowledge Graph, this network doesn’t just store fragmented data points — it actively maps the relationships between them and uncovers unexpected connections that would otherwise remain hidden. This is the essential architectural leap: from a passive, siloed record of what happened to a living, connected digital twin that can model what could happen next.

Why Knowledge Graphs Matter for RWD

RWD is notoriously fragmented, multi-modal, and siloed. A patient’s journey is scattered across:

• Clinical Data: EHR/EMR records (diagnoses, procedures)
• Genomic Data: Sequencing reports (mutations, biomarkers)
• Imaging Data: MRIs, CT scans (tumor size, morphology)
• Outcomes Data: Registries, claims (survival, response)

Each of these dataset captures fragments of the patient journey, yet fails to tell the full story. A Knowledge Graph changes that. It is the semantic scaffolding that understands that a single patient’s record is not a flat file, but a network of relationships — a system of interconnected biological and clinical realities.

The Knowledge Graph doesn’t just store this data; it harmonizes and connects it. It creates a unified map that understands that a gene mutation (from a genomic report) is linked to a protein pathway, which is the target of a drug (from a formulary), which was administered to a patient (from an EHR), who exhibited a specific outcome (from a registry).

This connected blueprint is the engine for true insight generation. It fundamentally changes the questions a Leader organization can ask.

• An Executor asks: “How many patients in our database have the KRAS G12C mutation?”
  This is a simple database query.
• A Leader asks: “Which patients with KRAS G12C, who failed first-line chemotherapy, share similar imaging-derived phenotypes and co-mutation profiles to known long-term survivors on our investigational drug?”
  This is a complex, multi-hop insight query that only a KG can answer.

This allows organizations to make the critical leap from isolated data points to interconnected, causal insights. This is the technical architecture that separates Leaders from the rest: models don’t just consume data; they continuously re-invest learnings back into the Knowledge Graph, growing its intellectual capital over time.

Data doesn’t just inform — it learns.

The Architecture of Understanding

In a Leader organization, the Knowledge Graph serves as the semantic backbone of the RWD digital twin.
It integrates three critical dimensions:

1. Entity Understanding: Harmonizing data across ontologies like SNOMED, ICD, UniProt, and DrugBank ensures that “lung carcinoma” and “non-small cell lung cancer” resolve to the same clinical reality.
2. Relationship Intelligence: Mapping how drugs modulate targets, how those targets link to pathways, and how pathways alter disease trajectories creates interpretable AI models that explain why outcomes occur, not just what outcomes occur.
3. Temporal Context: Capturing longitudinal patient events enables predictive simulations-the foundation for digital twins of RWD, where patient journeys can be modeled, tested, and optimized virtually.

This graph-driven infrastructure becomes a cognitive substrate — the space where federated learning models train, reason, and evolve without compromising data privacy.

Trust Graph (the collaboration layer)

But these partnerships can’t be built on tech alone. They run on an equally critical infrastructure: Trust.

If a Knowledge Graph connects data, a Trust Graph connects the institutions that own it.

Get Partex.AI’s stories in your inbox

Join Medium for free to get updates from this writer.

Remember me for faster sign in

In the Leader model, value isn’t created in isolation. It’s created when hospitals, biotechs, CROs and pharma companies collaborate for training models on shared data without ever moving or exposing it. This federated model is the future, but it has one absolute prerequisite: verifiable trust.

Patient-Centric Design for biobanks to interact with hospitals and research centers

Leader biobanks recognize a fundamental market reality: hospitals and research centers cannot and will not compromise patient data sovereignty. In an environment where GDPR and HIPAA violations carry existential penalties, data security isn’t negotiable.

This creates a strategic imperative. The traditional biobank model “deposit your samples and data with us” is structurally incompatible with institutional risk tolerance. Collaborations stall not from lack of scientific alignment, but from misaligned incentives around data control.

The competitive advantage goes to biobanks that invert the value exchange:

The Old Paradigm: “Can you send us your data?”
The New Paradigm: “Our models come to your data. It never leaves your firewall. You retain complete control, visibility, and ownership.”

This isn’t simply better compliance, it’s a superior business model. By architecting trust into the infrastructure rather than negotiating it case-by-case, Leader biobanks unlock network effects that Emerging competitors cannot access.

The Trust Infrastructure Consent as a Protocol:

In this new model, trust isn’t a handshake, it’s built directly into the system’s plumbing. The Trust Graph is the technical and legal framework that makes collaboration safe and provable.

Its most powerful component is transforming consent from a static document into a dynamic, living protocol.

Traditional Consent: A scanned PDF in a silo, separate from the data. A passive record of a past event.

Executable Consent: A digital rule attached to the data. It travels with the data.

This consent as a protocol lets the system automatically enforce a patient’s wishes in real-time.

For example: A patient’s data might have a rule or selective consent: This genomic and imaging data can be used for non-commercial oncology research only. It cannot be used for any commercial purpose and must be anonymized.

When an AI model queries that data, the system first checks the model’s credentials against the patient’s active consent. If it’s a commercial query, access is automatically denied. This builds a provably trustworthy system, letting hospitals collaborate with confidence that patient rules are being enforced by the architecture itself.

Sample Logistics as Cash Flow Management:

Think of the Knowledge Graph as turning static data into usable capital. The Trust Graph is the system that governs how that capital moves — who can access it, under what rules, and with full auditability.

Every transaction ,every query, every model trained, every insight generated is logged in a permanent, auditable record(Blockchain is truly immutable and is the highest standard for audit trail). This is Data Governance in practice, creating a full, transparent history of how an insight was generated.

This auditable trail is what allows leaders to finally measure the KPIs that define a Leader organization:

• Returns on Data : We can trace exactly which data assets (from which partners) contributed to a high value discovery.
• Data Utilization Rate: We can identify shelf assets that aren’t participating in the loop and prioritize their digitization.
• Monetizable Intelligence: This ledger(if blockchain) provides the basis for a new economy or rather generates a new revenue stream. Partners are compensated for the value of the insights their data helped create, not by selling their data but rather licensing their intelligence.

The Trust Graph, therefore, completes the economic loop. It ensures that as intelligence flows out, tangible value flows back to the data’s origin or the data contributors, building a truly self-sustainable and collaborative ecosystem.

Strategic Value: From Data Assets to Cognitive Capital

In the same way financial institutions evolved from vaults of static cash to engines of transactable capital, the modern biobank must evolve from a frozen archive to a cognitive enterprise — where every dataset compounds in value and every model generates measurable return. The biobank’s value proposition is shifting — from how much data it holds to how much intelligence it creates. This shift is not abstract — it’s operational, measurable, and strategic.

Key performance levers for biobank leaders include:

1. Time-to-Insight (TTI): Reducing analytic latency from months to hours.
2. Data Utilization Rate: % of samples linked to multimodal digital data.
3. Predictive Yield: Fraction of models producing actionable hypotheses.
4. Cognitive Return on Data (CRoD): Rate at which new data increases AI ecosystem predictive power.
5. Monetizable Intelligence: Federated model licensing and AI-driven revenue streams without raw data exchange.

Here is how the shift looks like for archetypes in biobanks.

Call to Collaboration

The future of biobanking will not be built on frozen samples or static data warehouses — it will be built on living knowledge graphs that think.

• Every dataset is a deposit of biological intelligence.
• Every model is an interest-bearing instrument.
• Every institution that connects these dots builds cognitive capital — a durable and defensible advantage.

Partex.AI is architecting this infrastructure: integrating multimodal RWD, harmonized ontologies, and explainable AI into a unified platform that accelerates the biobank’s journey from Executor to Leader.

“The transformation of RWD into living intelligence isn’t a Partex vision alone — it’s a shared mandate for the biomedical ecosystem. But those who build cognitive capital today will define the science of tomorrow.”

The question is no longer if to build your biobank intelligence pipeline —
it’s how fast you can deploy it before your competitors do.

Contact Partex.AI to discuss how federated architecture, explainable AI, or agentic systems can accelerate your organization’s journey from Executor to Leader in 2026.

Ready to shape the future of healthcare AI? Subscribe to our newsletter for exclusive insights on ecosystems, innovation strategies, and technology ROI.

Author Bios

Dr. Sanyogita Purandare, VP of Data Science
Dr. Purandare is an expert in AI-driven drug discovery, specializing in multimodal learning, generative AI, and predictive modeling. She has developed AI models that accelerate drug development and optimize pharmaceutical R&D. With leadership roles at global pharma, biotech, and manufacturing corporations, she has delivered AI solutions that reduced costs and improved efficiency. Recognized among GlantorX’s 100 Faces Women Leaders, she has a proven ability to lead cross-functional teams and drive AI innovation.

Dr. Swati Gaikwad, Manager — Data Quality at Partex.AI
Swati holds a Ph.D. in Biotechnology, from University of Pune, and brings extensive subject-matter expertise in the life science domain. She specialized in precision oncology and she applies her expertise to manage and maintain high-quality oncology databases and actively contribute to product development. She is passionate about harnessing AI-driven technologies to transform complex life-science data into actionable clinical insights. As an expert in ontology and semantic data structuring, she plays a key role in developing and scaling biomedical knowledge graphs, ensuring they are structured, accurate, and production-ready for real-world applications. She helps build robust, scalable data intelligence systems that accelerate discovery pipelines, and support enterprise-level decision making.

Nimish Ashtekar, Growth Analyst

Mr. Ashtekar is a dynamic healthcare professional, specializing in AI and blockchain applications , data acquisition , and digital health strategy. He has proposed and positioned AI solutions that support digital transformation and enhance patient outcomes for healthcare organizations and pharma. With experience in consulting and business development across the global healthtech sector , he has delivered AI and data services that boosted model accuracy and secured multiple projects. He has a proven ability to lead B2B expansion initiatives and drive strategic digital health solutions.

Acknowledgment of Reviewers

This article greatly benefited from the insightful reviews and feedback provided by:

Dr. Gunjan Bhardwaj, CEO & Founder at Partex.AI
Gunjan is a recognized global leader in AI & Lifesciences. He has
various patents and has authored two books as well as published
various articles in prestigious journals like Harvard Business
Review and MIT Sloan Review. Gunjan studied at IIT Bombay and
European Business School, Germany. He has served on the
advisory boards of various Pharmaceutical companies, Think
Tanks and Not for profits.
He has been honored with various awards such as Germany’s “40
under 40” by Capital Magazine, Leader of the future reality by
BCG-Handelsblatt and the “Excellent Leader with an Immigration
Background” by the City of Frankfurt. Gunjan was also ranked as
one of the most influential people in the new normal by Focus
Magazine in Germany.

Gaurav Tripathi, Group CTO at Partex.AI
Gaurav Tripathi is a serial entrepreneur and the Co-founder & Group CTO of Partex.AI, with 19+ years of experience across video, big data, blockchain, and AI. An IIT Bombay alumnus, he has led the filing of 175+ patents, with 45 listing him as an inventor, and has been recognized with honors like the Warrior of Change Award, BW Disrupt 40 Under 40, Healthcare Excellence Award, and the Global Spin Award for Digital Transformation Leader of the Year.

Vatsal Agarwal, Senior Vice President at Partex.AI
Vatsal drives strategic leadership in AI-powered analytics for life sciences with 30+ patents and ‘ Healthcare 40 under 40’ awarded by Business World. A graduate of The Johns Hopkins University and Indian Institute of Technology (IIT) Roorkee, he is leading initiatives to generate real-world evidence, accelerate drug discovery and optimize clinical trials for 20 years, while fostering impactful partnerships across the industry.